Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention

Prior treatment

• Concomitant treatment with other antineoplastic drugs including investigational endocrine therapies
• Serious uncontrolled concomitant medical condition or disease including active, uncontrolled infections

Other illness

• Special histotypes of prostate cancer
• Patients with dementia or psychiatric illness that limit compliance with study requirements or that may prevent understanding and/or signing informed consent.

Other

• Patients with PSA \> 100 ng/ml at diagnosis
• Inability to perform MRI (pacemaker wearers, claustrophobia...) or MRI of inadequate quality to obtain the HA3DTM 3D reconstruction

• Signature of the written informed consent and consent to the use of personal data
• Age \> 40 years and male sex
• Pre-operative MRI performed according to ESUR recommendations and reporting in accordance with PiRads V.2
• Disease with evidence of bulging or radiological T3 on pre-operative MRI
• Histological diagnosis of acinar type prostate cancer in the area highlighted on MRI
• Absence of bulky (\>3 cm), bony or visceral retroperitoneal or pelvic lymph node metastatic lesions
• Patients eligible for radical prostatectomy + pelvic lymphadenectomy
• ECOG PS 0-1
• Life expectancy ≥ 5 years
• Patients motivated to preserve erection and with pre-operative sexual activity with IIEF \>17
• Availability of the patient's pre-operative clinical data
• Patients must be available to carry out the visits foreseen in the follow-up of the protocol and consent to data collection